ARCHIVES

Phase III Xtandi Trial Meets Primary Endpoints Of Progression-Free and Overall Survival

This article is from The Cancer Letter archive.

Vol. 36 No. 11 | November 29, 2013

Download PDF Visit The Full Archive

Related Articles

In Brief: New Presidents Take Office At ONS, ONCC, ARS; Baird Wins Awards; New VP In Houston

July 8, 1994

Decision To Stop NSABP P-4 Study Before It Starts Shocks Clinical Trialists.

March 2, 2007

Bypass Budget For FY 1992 Shown In Chart

May 18, 1990

Women’s Health Study To Supplant Need for WHT, Greenwald Says

May 31, 1991

In Brief: New NIH Grant Program Offers Up To $1 Million a Year For Centers At Minority Institutions

January 25, 1985

NCI Approved Clinical Trials

May 28, 2010